uploads/2018/05/Diversified.png

A Performance Review of Merck’s Diversified Products

By

Updated

Respiratory brands

Merck & Company’s (MRK) Singulair, a drug for the prevention and treatment of asthma, reported revenue of $175 million in Q1 2018 compared to $186 million in Q1 2017, a ~6% YoY (year-over-year) fall and a ~4% sequential fall.

Singulair generated revenues of $170 million in international markets and $6 million in the US market in Q1 2018. In the asthma drug market, Singulair’s peers include AstraZeneca’s (AZN) Accolate.

Nasonex, a drug for the treatment of nasal allergy symptoms, generated revenue of $122 million in Q1 2018 compared to $139 million in Q1 2017, a ~12% YoY fall and a ~2% sequential rise.

In Q1 2018, Nasonex generated revenues of $121 million in international markets and $1 million in the US market.

Dulera, an inhalation aerosol for asthma, reported revenue of $57 million in Q1 2018 compared to $82 million in Q1 2017, a ~30% YoY fall and a 26% sequential fall.

Dulera generated revenue of $50 million in the US market and $7 million in international markets in Q1 2018. In the marketplace, Dulera faces stiff competition from AstraZeneca’s Symbicort and Pulmicort, Teva Pharmaceutical’s (TEVA) QVAR, and GlaxoSmithKline’s (GSK) Flovent.

Article continues below advertisement

Other diversified branded drugs

Cozaar/Hyzaar generated revenue of $120 million in Q1 2018 compared to $112 million in Q1 2017, a ~7% YoY rise and a 4% sequential fall.

In Q1 2018, Cozaar generated revenues of $7 million in the US market and $113 million in international markets.

Arcoxia generated revenue of $83 million in Q1 2018 compared to $103 million in Q1 2017, representing a ~19% YoY fall and a ~9% sequential fall.

Fosamax reported revenue of $55 million in Q1 2018 compared to $61 million in Q1 2017, a ~10% YoY fall and an 11% sequential fall.

Advertisement

More From Market Realist